Hematology Analyzer Market to Surpass US$ 3.5 Billion by 2034, Fueled by Automation and Advanced Diagnostics

Increasing Prevalence of Blood Disorders and Chronic Diseases Escalates the Adoption of Hematology Analyzers.

The global hematology analyzer market size is expected to generate around US$ 2,007.8 million in sales in 2024. With a predicted CAGR of 5.7%, the hematology analyzer industry is projected to reach a worth of around US$ 3,502.2 million by the end of 2034.

Due to advancements in several fields, including pharmacogenomics, hemoglobinopathies, genetic treatments, bleeding disorders, stem cell research, and proteomics, the global hematology analyzer industry is projected to expand significantly over the forecast period. Similar to how the global hematology market has grown, this trend is expected to continue over the forecast period due to increased public awareness and the consolidation of diagnostic laboratory chains.

The global hematology analyzer market is driven by increasing inclinations toward high-sensitivity hematological testing and rising adoption rates of automated hematology instruments. The expansion of high-capacity hematology analyzers and the introduction of basic cytometry methods analyzers, among other examples of increasing technological advancement, have propelled market expansion and are predicted to continue.

The fierce rivalry between the leading hematology analyzer vendors and the expensive nature of hematology analyzers are expected to limit the market expansion. Over the projected period, the market expansion for hematology analyzers is anticipated to be constrained by regulatory policies that are time-consuming and rigorous.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=9392

Regional Outlook

Due to its high disposable income and the adoption of automated hematology instruments by diagnostic laboratories, North America has recently led the hematology analyzer market in revenue share. Due to the abundance of untapped opportunities, particularly in the developing economies of China and India, Asia Pacific to advance rapidly during the projection period.

The hematology analyzer market is expanding due to rising disease incidence, improved healthcare facilities' knowledge, and population growth; the upward trajectory is anticipated to continue.

Key Takeaways

• The 5-part differential hematology analyzer segment in the product category to grab a share of 68.1% by 2034.
• The 6-part differential hematology analyzer segment in the product category is to exhibit a CAGR of 6.3% from 2024 to 2034.
• In the modality category, the standalone segment is to acquire a market share of 54% by 2034.
• In the modality category, the standalone segment is anticipated to accelerate at a CAGR of 5.8% between 2024 and 2034.
• In the end user category, the hospital segment is to acquire a market share of 44.3% by 2034.
• The hospitals segment in the end user category to exhibit a CAGR of 6.0% from 2024 to 2034.
• The North America hematology analyzer market is anticipated to surge at a CAGR of 5.2% by 2034.
• East Asia hematology analyzer industry to develop at a CAGR of 7.2% through 2034.
• The United States sales of hematology analyzers are anticipated to surge at a CAGR of 5.1% by 2034.
• Canada hematology analyzer sales to develop at a CAGR of 5.9% through 2034.
• Mexico's sales of hematology analyzers are anticipated to evolve at a CAGR of 5.3% by 2034.
• China's hematology analyzer sales are expected to surge at a CAGR of 7.6% until 2034.
• Japan's hematology analyzer market to exhibit a CAGR of 6.3% by 2034.
• South Korea's hematology analyzer industry is anticipated to boost at a CAGR of 6.8% by 2034.

“With the frequency of blood disorders rising, technical breakthroughs advancing, and healthcare spending rising, the hematology analyzer market is expected to increase significantly. The hematology analyzer vendors must concentrate on innovation and calculated partnerships to exploit novel opportunities.” opines a Fact.MR Analyst

Competitive Analysis

The hematology analyzer vendors are primarily concerned with creating cutting-edge technologies to satisfy user needs. Several hematology analyzer providers also engage in frequent mergers and acquisitions as a primary tactic to preserve a sizable market share. It is anticipated that these factors are going to stimulate market expansion for hematology analyzers.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=9392

Novel Developments

• In February 2022, Abbott announced the first dual-chamber leadless pacemaker patient implants in history as a part of its significant clinical research project, AVEIR DR i2i. During the pivotal study, one considerable advancement in leadless pacing technology was the initial worldwide implantation of Abbott's experimental Aveir dual-chamber leadless pacemaker.
• Sysmex Europe introduced the XQ-320, an automated three-part differential hematology analyzer, in April 2022. The XQ-320 provides exceptional quality in various clinical laboratory settings, combining new use levels and robust technology. It is a stable instrument that requires minimal sample volume, bench space, and maintenance in Europe.

Key Companies Profiled-

Sysmex Corporation; Abbott Laboratories; Thermo Fisher Scientific; Beckman Coulter Inc.; Balio Diagnostics; Bio-Rad Laboratories Inc.; Hycel; Mindray Medical International Limited; Spinreact; Siemens Healthcare; HORIBA, Ltd.; Dymind Biotech; NIHON KOHDEN CORPORATION

Industry News:

Abbott said in February 2022 that AVEIR DR i2i, the first dual-chamber leadless pacemaker patient implants in history, would take place as part of its groundbreaking clinical research initiative. During the crucial study, one significant development in leadless pacing technology was the first global installation of Abbott's experimental Aveir dual-chamber leadless pacemaker.

The groundbreaking BC-700 Series of hematology analyzers, which combines erythrocyte sedimentation rate (ESR) and complete blood count (CBC) assays, was introduced by Mindray in March 2022.

In April 2022, Sysmex Europe unveiled the XQ-320, an automated three-part differential hematology analyzer. The XQ-320 combines new use levels with reliable technology to deliver outstanding quality in various clinical laboratory scenarios.

Nihon Kohden India opened a new hematology analyzer reagent facility in May 2022.

The FDA approved Siemens Healthineers' RAPIDPoint 500e Blood Gas Analyzer in April 2020 so that it could be used in acute care settings with patients who were very sick. Now available in the United States for critical care testing, the RAPIDPoint 500e Blood Gas Analyzer is already available in countries requiring CE certification.

Beckman Coulter released the DxH 560 AL, a tabletop hematology analyzer, in January 2020. With one of the smallest aspiration volumes available on the market, the DxH 560 AL requires just a 17 L sample less than a drop of blood, making it the perfect tool for patients who are challenging to draw.

Explore More Related Studies Published by Fact.MR Research:

The global biopsy forceps market is set to enjoy a valuation of US$ 260.8 million in 2022, and further expand at a CAGR of 4% to reach US$ 317.3 million by the year 2027.

The global sales of dental services in 2021 was held at US$ 326.3 Biilion. With 6.6%, the projected market growth during 2022 to 2032

Increasing at a CAGR of 6%, the global women's health rehabilitation products market is predicted to increase from its current valuation of US$ 3.22 billion and reach US$ 5.77 billion by the end of 2033.

The global ENT medical devices market is gaining traction and likely to ascend at around 5.5% CAGR during the forecast period of 2021 to 2031.